These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12969089)

  • 61. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
    Zhang M; Chen CY; Wang XT; Lyu B
    Zhonghua Nei Ke Za Zhi; 2017 May; 56(5):368-374. PubMed ID: 28460509
    [No Abstract]   [Full Text] [Related]  

  • 62. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
    Romano M; Cuomo A; Gravina AG; Miranda A; Iovene MR; Tiso A; Sica M; Rocco A; Salerno R; Marmo R; Federico A; Nardone G
    Gut; 2010 Nov; 59(11):1465-70. PubMed ID: 20947881
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.
    Federico A; Nardone G; Gravina AG; Iovene MR; Miranda A; Compare D; Pilloni PA; Rocco A; Ricciardiello L; Marmo R; Loguercio C; Romano M
    Gastroenterology; 2012 Jul; 143(1):55-61.e1; quize e13-4. PubMed ID: 22484118
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.
    Chuah SK; Hsu PI; Chang KC; Chiu YC; Wu KL; Chou YP; Hu ML; Tai WC; Chiu KW; Chiou SS; Wu DC; Hu TH
    Helicobacter; 2012 Jun; 17(3):216-23. PubMed ID: 22515360
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
    Gisbert JP; Pérez-Aisa A; Bermejo F; Castro-Fernández M; Almela P; Barrio J; Cosme A; Modolell I; Bory F; Fernández-Bermejo M; Rodrigo L; Ortuño J; Sánchez-Pobre P; Khorrami S; Franco A; Tomas A; Guerra I; Lamas E; Ponce J; Calvet X;
    J Clin Gastroenterol; 2013 Feb; 47(2):130-5. PubMed ID: 22647827
    [TBL] [Abstract][Full Text] [Related]  

  • 69. First-line triple therapy with levofloxacin for Helicobacter pylori eradication.
    Gisbert JP; Fernández-Bermejo M; Molina-Infante J; Pérez-Gallardo B; Prieto-Bermejo AB; Mateos-Rodríguez JM; Robledo-Andrés P; González-García G
    Aliment Pharmacol Ther; 2007 Aug; 26(3):495-500. PubMed ID: 17635384
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.
    Goh KL; Manikam J; Qua CS
    Aliment Pharmacol Ther; 2012 May; 35(9):1097-102. PubMed ID: 22404486
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
    Lee H; Hong SN; Min BH; Lee JH; Rhee PL; Lee YC; Kim JJ
    Dig Liver Dis; 2015 Feb; 47(2):114-8. PubMed ID: 25467826
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
    Leow AH; Azmi AN; Loke MF; Vadivelu J; Graham DY; Goh KL
    J Dig Dis; 2018 Nov; 19(11):674-677. PubMed ID: 30307122
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.
    Qian J; Ye F; Zhang J; Yang YM; Tu HM; Jiang Q; Shang L; Pan XL; Shi RH; Zhang GX
    Helicobacter; 2012 Dec; 17(6):478-85. PubMed ID: 23067317
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study.
    Chen LW; Chien RN; Chang JJ; Fang KM; Chang LC
    Int J Clin Pract; 2010 Oct; 64(11):1530-1534. PubMed ID: 20846200
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
    Hu TH; Chuah SK; Hsu PI; Wu DC; Tai WC; Chiu YC; Wu KL; Kuo CM; Hu ML
    Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
    [TBL] [Abstract][Full Text] [Related]  

  • 77. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
    Prapitpaiboon H; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
    Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
    Gisbert JP; Bermejo F; Castro-Fernández M; Pérez-Aisa A; Fernández-Bermejo M; Tomas A; Barrio J; Bory F; Almela P; Sánchez-Pobre P; Cosme A; Ortiz V; Niño P; Khorrami S; Benito LM; Carneros JA; Lamas E; Modolell I; Franco A; Ortuño J; Rodrigo L; García-Durán F; O'Callaghan E; Ponce J; Valer MP; Calvet X;
    Am J Gastroenterol; 2008 Jan; 103(1):71-6. PubMed ID: 17764498
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Acid-related diseases. What is the current rescue treatment of choice for Helicobacter pylori: quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) or triple therapy with proton pump inhibitor, amoxicillin and levofloxacin?].
    Calvet X
    Gastroenterol Hepatol; 2008; 31(6):400-1. PubMed ID: 18570821
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.